A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy (REaCT-5G)
Latest Information Update: 08 Feb 2024
At a glance
- Drugs Filgrastim (Primary) ; Pegfilgrastim (Primary)
- Indications Chemotherapy-induced damage; Febrile neutropenia
- Focus Therapeutic Use
- Acronyms REaCT-5G
- 09 Dec 2023 Primary endpoint has not been met. (Bone pain)
- 09 Dec 2023 Results presented at the 46th Annual San Antonio Breast Cancer Symposium
- 21 Mar 2023 Status changed from recruiting to active, no longer recruiting.